About Company

Cipla was established in 1935 with the vision of making India self-reliant and self-sufficient in healthcare. Today, we are one of the world's largest generic pharmaceutical companies with a presence in over 170 countries. We are renowned for making affordable, world-class medicines that meet the needs of patients across therapies. We also offer services like consulting, commissioning, plant engineering, technical know-how transfer and support.

Incorporated 1935
Corporate Office Cipla Ltd., Mumbai Central, Mumbai 400 008, India
Chairman Dr. Yusuf K. Hamied
Executive Vice-Chairman Mr. M.K. Hamied
Listing Equity Shares: BSE Limited and National Stock Exchange of India Limited 
Global Depository Receipts: Luxembourg Stock Exchange
Turnover* USD 1.5 billion
Employees* 20,000
Approvals US FDA, WHO-Geneva, MHRA-UK, TGA-Australia, SUKL-Slovak Republic, APVMA-Australia, MCC-South Africa, PIC-Germany, Danish Medical Agency, ANVISA-Brazil, INVIMA- Colombia, NDA-Uganda, Department of Health-Canada and MOH-Saudi Arabia, among others
  • One of the world’s largest generic companies.
  • Over 2,000 products, 65 therapeutic categories, over 40 dosage forms.
  • 34 state-of-the-art manufacturing facilities approved by major international regulatory agencies.
  • Continuous innovation in R&D; over 20 world firsts.
Contact contactus@cipla.com
+91 22 23082891, +91 22 23095521